CLAIMS

- 1. A method for producing a human or animal plasma product or serum product comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in the plasma and
- (b) a step of filtering using a virus removal membrane after the step (a).
- 2. A method for producing a human or animal plasma product or a serum product comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal immediately after collection of the blood and reducing leukocytes in the plasma immediately after the above separation and
- (b) a step of filtering using a virus removal membrane after the step (a).
- 3. The method according to claim 1 or claim 2, wherein the virus removal membrane used in step (b) has an average pore diameter of 100 nm or less.
- 4. The method according to any one of claims 1 to 3, wherein the step (a) is a leukocyte-reducing step using a leukocyte removal membrane.
- 5. The method according to any one of claims 1 to 4, wherein the steps (a) and (b) are carried out under the

condition of a temperature of 25-40°C.

- 6. The method according to any one of claims 1 to 5, wherein the steps (a) and (b) are carried out under the condition of a pressure of 98 kPa or less.
- 7. The method according to any one of claims 1 to 6, wherein the amounts of blood passing through in the steps (a) and (b) are 100-500 ml, respectively.
- 8. The method according to any one of claims 1 to 7, wherein the treatment time for the step (b) is 40 minutes or less.
- 9. The method according to any one of claims 1 to 8, wherein the virus removal membrane used in the step (b) has an average pore diameter of 75 nm or less.
- 10. The method according to any one of claims 1 to 9, wherein the virus removal membrane used in the step (b) is a combination of a virus removal membrane having an average pore diameter of 75 nm and another virus removal membrane having an average pore diameter of 35 nm subsequent to the former membrane.
- 11. A human or animal plasma product or a serum product produced by a method comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in

the plasma and

 $\mbox{(b) a step of filtering using a virus removal membrane} \\ \mbox{after the step (a)} \, .$